Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design

2009307 citationsJournal Articlebronze Open Access

Authors

H.‐H. Parving · Copenhagen University Hospital

Barry M. Brenner · Brigham and Women's Hospital

John J.V. McMurray · University of Glasgow

Dick de Zeeuw · University Medical Center Groningen

Steven M. Haffner · Dermatology Clinical Research Center of San Antonio

Scott D. Solomon · Brigham and Women's Hospital

Nish Chaturvedi

Abstract

ALTITUDE will determine whether dual RAAS blockade with the direct renin inhibitor aliskiren in combination with an ACEi or ARB will reduce major morbidity and mortality in a broad range of high-risk patients with type 2 diabetes.

Topics & Keywords

Renin-Angiotensin System Studies Blood Pressure and Hypertension Studies Hormonal Regulation and Hypertension

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Nephrology Dialysis Transplantation

Volume 24, Issue 5, pp. 1663-1671

DOI: 10.1093/ndt/gfn721

Field-Weighted Citation Impact: 37.72